手术用人工血管市场 - 预测(2021年~2026年)

Vascular Graft Market - Forecasts from 2021 to 2026

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 118 Pages | 商品交期: 最快1-2个工作天内

  • 全貌
  • 简介
  • 目录





第1章 简介

  • 市场定义
  • 市场区隔

第2章 调查手法

  • 调查资料
  • 假设

第3章 摘要整理

  • 调查的重点

第4章 市场动态

  • 市场推动因素
  • 市场阻碍因素
  • 波特的五力分析
    • 供给企业的竞争力
    • 购买企业的竞争力
    • 新加入业者的威胁
    • 替代品的威胁
    • 功能的竞争企业间的竞争关系
  • 功能价值链分析

第5章 各材料:手术用人工血管市场分析

  • 简介
  • 人工
  • 混合
  • 生物材料

第6章 各适应症:手术用人工血管市场分析

  • 简介
  • 心血管疾病
  • 肾脏疾病
  • 动脉瘤
  • 其他

第7章 各终端用户:手术用人工血管市场分析

  • 简介
  • 医院和诊所
  • 门诊病人手术中心

第8章 各地区:手术用人工血管市场分析

  • 简介
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 其他
  • 中东和非洲
    • 以色列
    • 沙乌地阿拉伯
    • 其他
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 台灣
    • 泰国
    • 印尼
    • 其他

第9章 竞争环境与分析

  • 主要企业策略分析
  • 新兴企业和市场收益性
  • 合并,收购,协定,共同研究
  • 供应商竞争力 矩阵

第10章 企业简介

  • Hancock Jaffe Laboratories, Inc.
  • Getinge Group
  • W. L. Gore & Associates
  • Vascular Flow Technologies
  • C. R. Bard, Inc.
  • Artegraft Inc.
  • Vascular Genesis
  • B. Braun Melsungen AG
  • LeMaitre Vascular, Inc.
  • Terumo Aortic
Product Code: KSI061611564

The global vascular graft market is projected to grow at a CAGR of 5.04% to reach US$7.955 billion by 2026, from US$5.637 billion in 2019

A vascular graft is a surgical technique that reconnects blood arteries to shift blood flow from one part of the body to another. The most common reason for vascular grafting is to increase blood flow to an organ fed by a damaged artery by bypassing a total or partial obstruction. These grafts range in size from 5-8 mm in diameter. This allows the body's blood flow to return to normal. Catheter-based devices are inserted through a small incision and guided with the use of real-time imaging technology in vascular transplant surgeries. Development of efficient and advanced novel products using tissue-engineered and biological materials, increased public awareness of peripheral artery diseases and coronary diseases, increased government initiatives around the world propel the global vascular graft market during the forecast period. The major growth drivers of the vascular graft market are the growing incidence of cardiovascular illnesses such as hypertension, coronary artery disease, and cardiac aneurysms, as well as the rising prevalence of diabetes. Moreover, increased vascular graft usage in emerging nations such as China, India, and others would open up new potential for the vascular graft market.

The vascular graft market growth is anticipated to be further aided by the rise in the senior population, technological improvements, and changes in lifestyle (consumption of junk food, cigarettes, and alcohol). The growing prevalence of end-stage renal diseases (ESRD) has further boosted the demand for vascular grafting during the forecast period. Dialysis, which is often used by individuals with ESRD, is the sole option for kidney transplantation. Three times a week, hemodialysis is performed. Many patients' superficial veins have been depleted as a result of continuous dialysis, and vascular grafts are the only way to continue hemodialysis. In 2017, 124,500 new cases of ESRD were reported in the United States, with a crude (uncorrected) incidence rate of 370.2 per million per year. The number of people living with ESRD is increasing at a rate of around 20,000 each year.

Due to strong medical reimbursement facilities and technical advancements, North America has anticipated led the vascular graft industry. Due to a rapidly growing geriatric population, increased consumer awareness, increased healthcare expenditure, favorable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing countries such as China and India in this region, Asia Pacific is expected to grow at the fastest rate. The increased incidence of CKD, healthcare reforms, government efforts and investments, and rapid growth in the elderly population are all contributing to the Asia Pacific market's expanding growth. In addition, emerging markets such as Australia, Singapore, Japan provide various development possibilities for vascular grafts market participants because of an aging population and an increase in end-stage renal disease.

Growth Factors

The growing requirement for hemodialysis will fuel demand for vascular grafts

One of the major reasons for the growth of the global vascular graft market is the growing demand for hemodialysis. The growing need for hemodialysis products will boost demand for vascular grafts and propel the sector forward. Dialysis operations will become more common as the number of people with end-stage renal illness rises, as will the number of people with chronic kidney disease. Hemodialysis patients also require a well-functioning arteriovenous graft for a successful hemodialysis operation. According to research from the National Renal Foundation, 785,883 Americans suffered kidney failure in 2018 and required dialysis or a kidney transplant to live. As a result, the rising prevalence of chronic renal disease will lead to an increase in the number of hemodialysis procedures. Cook Medical's Zenith fenestrated endovascular graft earned FDA breakthrough device designation in March 2021. For life-threatening or profoundly disabling diseases or conditions, the product delivers more effective therapy or diagnosis. This strategy is anticipated to add value to the company's current portfolio while also generating money through sales. Furthermore, the increasing prevalence of cardiovascular illnesses throughout the world will drive up demand for vascular grafts.


Product recalls and failures to hinder the market growth during the forecast period.

A major restraint in the growth of the global vascular graft market is the product recalls and failures limiting the adoption of vascular graft during the forecast period. Patients might suffer serious or even fatal consequences as a result of product failures. Several businesses' goods have been recalled from the market throughout the years owing to product faults or other concerns. End-user perceptions of graft safety may be harmed as a result of market trends, which may influence their acceptance in treatment processes. As a result, the adoption of vascular grafts has been restrained during the forecast period.

COVID-19 Impact

The COVID-19 pandemic has had a great impact on the world as a whole and has led to economic breakdown and loss of life. Production activities are interrupted because of lockdown measures enforced in numerous countries. The COVID-19 impact on the global vascular graft market has been adverse owing to the production halt by industries due to the temporary lockdown implemented by several governments to break the cycle of the virus. The disruption in the demand and supply chain has further hampered the market in the forecast period. Despite the availability of OPD administrations at emergency clinics, the number of patient visits to clinics has fallen significantly in recent months. Despite this, patient visits to medical facilities have fallen significantly as a result of the lockdown in several countries. As a result, the number of suggestive tests has decreased. The sale of vascular grafts has also decreased as a result of this. Since the majority of vascular grafts and interventional techniques are elective, many of these procedures have been postponed. This is another issue that has a negative impact on the market for vascular grafts. However, in the post-COVID-19 scenario, the global vascular graft market is expected to boom with the increasing demand during the forecast period.

Competitive Insights

The market leaders for the pretreatment coating market are Hancock Jaffe Laboratories Inc., Getinge Group, W.L. Gore & Associates, Vascular Flow Technologies, C.R. Bard Inc., Artegraft Inc., Vascular Genesis, B. Braun Melsungen AG, LeMaitre Vascular Inc., and Terumo Aortic.


By Source

  • Synthetic
  • Semi-Synthetic
  • Natural

By Indication

  • Cardiovascular Diseases
  • Renal Diseases
  • Aneurysms
  • Others

By End-Users

  • Hospitals and Clinics
  • Ambulatory Surgical Centers

By Geography

  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • Indonesia
    • Taiwan
    • Thailand
    • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Vascular Graft Market Analysis, By Source

  • 5.1. Introduction
  • 5.2. Synthetic
  • 5.3. Semi-Synthetic
  • 5.4. Natural

6. Vascular Graft Market Analysis, By Indication

  • 6.1. Introduction
  • 6.2. Cardiovascular Diseases
  • 6.3. Renal Diseases
  • 6.4. Aneurysms
  • 6.5. Others

7. Vascular Graft Market Analysis, By End-User

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
  • 7.3. Ambulatory Surgical Centers

8. Vascular Graft Market Analysis, By Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. UK
    • 8.4.2. France
    • 8.4.3. Germany
    • 8.4.4. Italy
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. Israel
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. South Korea
    • 8.6.6. Thailand
    • 8.6.7. Taiwan
    • 8.6.8. Indonesia
    • 8.6.9. Others

9. Competitive Environment and Analysis

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. Company Profiles

  • 10.1. Hancock Jaffe Laboratories Inc.
  • 10.2. Getinge Group
  • 10.3. W.L. Gore & Associates
  • 10.4. Vascular Flow Technologies
  • 10.5. C.R. Bard Inc.
  • 10.6. Artegraft Inc.
  • 10.7. Vascular Genesis
  • 10.8. B. Braun Melsungen AG
  • 10.9. LeMaitre Vascular Inc.
  • 10.10. Terumo Aortic